Investor contact:Takashi Okubotakeda.ir.contact@takeda.com+81 3 3278 2306Media enquiries:Kazumi Kobayashi (Japan)Kazumi.kobayashi@takeda.com+81 3 3278 2095About Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical company headquartered in Japan, dedicated to advancing patients by translating science into highly innovative products Providing medicines with better health and a better future. Takeda focuses its R&D efforts on four therapeutic areas: oncology, rare diseases, neuroscience and gastroenterology (GI). In addition, we are making targeted investments in plasma-based therapies and vaccines. We are focused on developing highly innovative medicines that help transform people`s lives by pushing the boundaries of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust and modalities-diverse pipeline. Our employees are committed to improving the quality of life for patients and work with our healthcare partners in approximately 80 countries. www.takeda.com.Important For the purposes of this announcement, “press release” means this document, any oral presentation, question and answer session and any written or oral document discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) in connection with this press release. This press release (including oral statements and related questions and answers) is not intended to be an offer, solicitation or solicitation of an offer to buy, acquire, subscribe, exchange, sell or transfer securities or to solicit a vote or approval in any jurisdiction, and does not constitute an offer: does not constitute or form part of an offer to purchase, acquire, subscribe, exchange, sell or transfer securities. No shares or other securities are offered to the public with this press release. An offering of securities in the United States will be made only pursuant to registration or an exemption from registration under the U.S. Securities Act of 1933, as amended.

This press release (together with any other information provided to the recipient) is provided on the condition that it is used by the recipient for informational purposes only (and not to evaluate any investments, acquisitions, divestments or other transactions). Failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda has direct and indirect interests are separate entities. In this press release, “Takeda” is sometimes used for simplicity when referring to Takeda and its subsidiaries in general. Similarly, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or those who work for them. These terms are also used when the identification of the company(ies) in question does not serve any purpose. Forward-Looking StatementsThis press release and any documents distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda`s future business, condition and results of operations, including estimates, forecasts, objectives and plans for Takeda. Forward-looking statements often include, but are not limited to, words such as “objectives”, “plans”, “believes”, “hopes”, “continues”, “expects”, “seeks”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipate”, “estimate”, “project” or similar expressions or the negative thereof.

The forward-looking statements contained herein are based solely on estimates and assumptions made by Takeda as of the date of this press release. For more information on these and other factors that could affect Takeda`s results, performance, achievements or financial condition, see “Item 3. Key Information – D. Risk Factors” in Takeda`s most recent Annual Report on Form 20-F and other reports of Takeda filed with the U.S. Securities and Exchange Commission and available on Takeda`s website at www.takeda.com/investors/reports/sec-filings/ or less www.sec.gov. Takeda`s future results, performance, achievements or financial condition may differ materially from those expressed or implied by the forward-looking statements. Persons receiving this press release should not place undue reliance on forward-looking statements. Takeda undertakes no obligation to update any forward-looking statements contained in this press release or other forward-looking statements, except as required by law or securities law. Past performance is not indicative of future results and Takeda`s results in this press release may not be indicative of Takeda`s future results and are not an estimate, forecast or projection.

This statement and any materials distributed in connection with this statement may contain forward-looking statements, beliefs or opinions about Takeda`s future business, position and results of operations, including estimates, forecasts, objectives and plans for Takeda. Forward-looking statements often include, but are not limited to, words such as “objectives”, “plans”, “believes”, “hopes”, “continues”, “expects”, “seeks”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipate”, “estimate”, “project” or similar expressions or the negative thereof.